 Shares of Spectrum Pharmaceuticals Inc. SPPI, -4.27 were down 22.0 in premarket trading on Friday, the day after a Food and Drug Administration committee voted 9-4 that the benefits of the companys experimental lung-cancer drug do not outweigh the risks. The FDA is not required to follow the committees advice when deciding when to approve a new drug but often does. 